Skip to main content

Rational Drug Design of Selective Opioid Receptor Agonist TAN-821 and Antagonist TAN-1014

Buy Article:

$63.00 plus tax (Refund Policy)


β-Endorphin (β-EP) is generally classified as aμ;andδ;opioid receptor agonist but is also an agonist of theopioid receptor. Although several selective agonists and antagonists for m, d, and k opioid receptors are known, selectivereceptor agonists or antagonists have not been reported for some time. Recently, we designed and synthesized the selectivereceptor agonist, 17-(cyclopropylmethyl)-4,5α-epoxy-3,6β- dihydroxy-6,14-endoethenomorphinan-7α-[N-methyl-N-phenethyl]carboxamide (TAN-821), and the selective e receptor antagonist, 17-(cyclopropylmethyl)-4,5α-epoxy-6b,21-epoxymethano-3-hydroxy-6,14-endoethenomorphinan- 7α-(N-phenethyl)carboxamide (TAN-1014). TAN-821 stimulated binding of the nonhydrolyzable guanosine 5'-triphosphate analogue, guanosine 5'-(γ-thio)-triphosphate (GTPgS), to the mouse pons/medulla membrane via activation of thereceptor. Moreover, TAN-821 given intracerebroventricularly (i.c.v.) produced marked, lonγ;lasting, and dose-dependent antinociception in tail-flick and hot-plate tests. This antinociception induced by i.c.v. administered TAN-821 was blocked by i.c.v. pretreatment with the e opioid receptor partial agonist β-EP (1-27), but not theμ;opioid receptor antagonist β-FNA, theδ;opioid receptor antagonist NTI, or the k opioid receptor antagonist nor-BNI. On the other hand, i.c.v. injection of TAN- 1014 alone produced no antinociception, and i.c.v. pretreatment with TAN-1014 attenuated the antinociception induced by i.c.v β-EP. These results suggest that TAN-821 and TAN-1014 are respectively a selectivereceptor agonist and antagonist and that they may be useful tools for investigating the pharmacological properties of theopioid receptor.

Keywords: TAN-1014; TAN-821; accessory site theory; analgesics; e opioid receptor; message-address concept; β-endorphin

Document Type: Research Article


Affiliations: Pharmaceutical Research Laboratories, Toray Industries, Inc., 1111, Tebiro, Kamakura, Kanagawa, 248-8555, Japan.

Publication date: April 1, 2006

More about this publication?
  • Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more